Cantabio Pharmaceuticals Inc. (CTBO)

[XenaLives]

My reason for caution, as I understand this shares traded will more than double in December of this year. These shares previously had no value so the tech will be have to be incredible to keep the stock from tanking then:

_87102228_f0122482-alzheimer_s_disease,_illustration-spl-3



CTBO was formed last December after the merger with Gardedam Therapeutics Inc. Having completed the merger, Cantabio issued 15.5 million shares of its common stock to the holders of Gardedam common stock. Under the terms of the Merger, these shares will be restricted from trading for a period of one year from the closing of the Merger. After the close of the Merger a total of 27.25 million shares of common stock will be outstanding. Cantabio CEO Gergely Toth said upon completion of the merger:

July 07, 2016 11:39 AM ET
Capital Markets
Company Overview of Cantabio Pharmaceuticals Inc. Prior to Reverse Merger with Gardedam Therapeutics, Inc.
Snapshot

People
Company Overview

As of December 17, 2015, Cantabio Pharmaceuticals Inc. was acquired by Gardedam Therapeutics, Inc., in a reverse merger transaction. Cantabio Pharmaceuticals Inc. does not have significant operations. It intends to merge with or acquire an entity in the pharmaceutical industry. The company was formerly known as Lion Consulting Group, Inc. and changed its name to Cantabio Pharmaceuticals Inc. in September 2015. Cantabio Pharmaceuticals Inc. was founded in 2012 and is based in Palo Alto, California.